Yasmin Trachsel

Kantonsspital Winterthur

Papers

1

Total Citations

28

H-Index

1

About

Dr. Yasmin Trachsel is a clinician-researcher whose work focuses on rare genitourinary malignancies and the molecular mechanisms driving treatment resistance. Her most cited study, a 2020 case report on an inflammatory myofibroblastic tumor (IMT) of the bladder with an FN1-ALK gene fusion, has garnered 28 citations and provides critical insight into the variable efficacy of ALK inhibition. In this landmark paper, Dr. Trachsel documented a patient whose advanced, unresectable IMT failed to respond to neoadjuvant crizotinib, challenging the assumption that all ALK-rearranged tumors are uniformly sensitive to targeted therapy. This contribution has shaped clinical decision-making for rare bladder sarcomas and highlighted the need for alternative strategies in fusion-specific contexts. Her work bridges surgical pathology and precision oncology, offering a nuanced understanding of how gene fusions influence drug response. With a growing citation footprint, Dr. Trachsel is establishing herself as a key voice in the molecular characterization of urologic tumors, advancing personalized treatment approaches for patients with otherwise limited options.

Research Focus

Key Achievements

1
H-Index
1
Papers
28
Total Citations
28
Avg Citations/Paper
🏆 Most Cited Paper
Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition
28 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: Kantonsspital Winterthur

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago